Bioxcel Therapeutics Inc

This study tested a new oral drug, BXCL701, combined with the immunotherapy pembrolizumab for men with advanced prostate cancer that had stopped responding to standard treatments. The goal was to find a safe dose and see if the combination could help control the cancer. It focuse…

This study tested whether a dissolving film medication called BXCL501 can safely reduce agitation episodes in people with dementia. About 150 participants aged 65+ living in care facilities received either a low dose, high dose, or placebo film when agitation occurred over 12 wee…

This study tested a medication called BXCL501 to see if it could safely and effectively calm episodes of agitation when used at home by adults with schizophrenia or bipolar disorder. In the second part of the trial, 452 participants used the medication as needed over 12 weeks at …

This study looked at what happens when people with schizophrenia or bipolar disorder stop taking a short-term medication for agitation. Researchers gave 29 adults the drug Igalmi as needed for 7 days to calm agitation episodes, then monitored them for 3 days after stopping. The m…